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CDKN2A (encodes p16
INK4A and p14
ARF) deletion, which results in both Rb and p53 inactivation, is the most common
chromosomal anomaly in human cancers. To precisely map the deletion breakpoints is important to understanding the
molecular mechanism of genomic rearrangement and may also be useful for clinical applications. However, current methods
for determining the breakpoint are either of low resolution or require the isolation of relatively pure cancer cells, which can be
difficult for clinical samples that are typically contaminated with various amounts of normal host cells. To overcome this
hurdle, we have developed a novel approach, designated Primer Approximation Multiplex PCR (PAMP), for enriching
breakpoint sequences followed by genomic tiling array hybridization to locate the breakpoints. In a series of proof-of-concept
experiments, we were able to identify cancer-derived CDKN2A genomic breakpoints when more than 99.9% of wild type
genome was present in a model system. This design can be scaled up with bioinformatics support and can be applied to
validate other candidate cancer-associated loci that are revealed by other more systemic but lower throughput assays.
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INTRODUCTION
Tumors evolve through the continuous accumulation and
selection of randomly mutated genes. While sets of advantageous
mutations are selected in tumors, neutral or even slightly detri-
mental mutations may also occur due to genomic instability and
genetic drift. Recently, much effort has been expended to identify
in primary human cancers point mutations in the exons of cancer-
related genes. However, systemic mapping of genomic DNA
rearrangements has lagged behind, due to technical diffi-
culties in detecting smaller deletions, tumor heterogeneity, and
the necessity to purify malignant from normal cells [1].
Historically, such work was done by time consuming and labor
intensive genetics and molecular cloning on established cancer cell
lines [2,3,4]. One of the most striking examples is the homozygous
deletion of the CDKN2A (INK4A/ARF) tumor suppressor locus,
which was discovered in this and other laboratories [3,4,5,6,7,8].
The CDKN2A deletions occur early during tumor development
[9,10,11]. The p16
INK4a (one of the CDKN2A products [12])
protein constrains cell cycle progression by the Rb pathway and
may be responsible for the decline in the replicative potential of
stem cells during aging [13]. The p14
ARF (the other alternative
reading frame of CDKN2A [14]) gene product regulates the
expression of MDM2, the turnover of p53, and thereby controls
the cellular response to stress (reviewed in [6,7,8,15,16,17]).
Because the Rb and p53 pathways are central to cancer gate-
keeping and caretaking [18,19], strong selection pressures exist for
the disruption of the entire CDKN2A gene segment on both
chromosomes. Few other deletions are as well characterized,
although it is expected that more will be found when more data
from array based comparative genomic hybridization (array-
CGH) are reported and also through The Cancer Genome Atlas
(TCGA) project [20,21,22,23,24]. It will be important to validate
the relevance of those genomic rearrangements to cancer
development since many of the genomic structural changes may
be simply due to genome instability in cancer. Large scale studies
with clinical samples will be the most reliable confirmation.
While point mutations and very small insertions or deletions in
genomic DNA can be detected by exon re-sequencing, it can be
more difficult to detect gene dosage changes of larger genomic
fragments, especially deletions [1]. Current established techniques
for deletion mapping, including Southern blotting [25], fluorescent
in situ hybridization (FISH) [26], quantitative PCR [26,27,28,
29,30], and array-CGH [31] rely on the absence of a detectable
wild type signal [1]. This is problematic when a significant number
of normal cells are present in a tumor sample. Array-CGH has the
potential to analyze alterations of DNA copy number on a genome-
wide scale with relatively high resolution, depending on whether
BACs, PCR products or oligonucleotides are used for the array
elements. However, these techniques often fail where there is
a heterogeneous cell population or samples of poor quality [31].
FISH is less vulnerable to the presence of heterogeneous cell
populations, but has relatively low resolution and is difficult to
scale up. Except for FISH, the other techniques mentioned are not
practical for mapping genomic translocations and inversions. End-
sequencing profiling was developed to address this issue but the
approach was costly and hard to scale up [32]. Therefore, there is
a need to develop a scalable approach for detecting such genomic
structural changes in solid tumors where heterogeneous cell
populations are present.
Here we report a novel approach, designated as Primer
Approximation Multiplex PCR (PAMP), to enrich small amounts
of deleted genomic DNA sequences in the presence of wild type
DNA. The genomic locations of the enriched sequences are
subsequently decoded by a genomic tiling array and confirmed by
sequencing.
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CDKN2A locus
The CDKN2A is located on chromosome 9p21 (Figure 1). It
encodes two proteins in different reading frames: p16
INK4A and
p14
ARF, which both have 3 exons and share exons 2 and 3.
CDKN2B (p15
INK4B) and MTAP (methylthioadenosine phosphor-
ylase) (not shown) are centromeric and telomeric neighboring
genes respectively [3,17,33,34]. BAC clone RP11-149I2 contains
the whole CDKN2A genomic fragment and was used as template to
generate probes (excluding repetitive regions) for printing on the
minigenomic tiling array. The frequency of repetitive sequences
predicted by RepeatMasker is shown at the bottom of the diagram.
Primer Approximation Multiplex PCR (PAMP)
It is difficult to detect a small fraction of deleted mutant genomic
DNA in the presence of a vast excess of wild type DNA with array
CGH or other popular molecular biology tools [26,27,35]. In
typically contaminated tumor samples, genomic DNA is composed
of various ratios of WT and CDKN2A deficient DNA. We aimed to
take advantage of the fact that a shorter deleted genome sequence
should be preferentially amplified compared to a much longer WT
sequence using ‘‘approximated’’ flanking primers (Figure 2A) [36].
The approach is illustrated in Figure 2. In this example, rela-
tively even-spaced primers (average 1 kb apart) surrounding the
locus of interest are divided into 20 groups for PCR. There are 10
groups each of forward primers, F1, F2 …, F10 and reverse primer
R1, R2, …,R10, respectively (Figure 2A). Therefore, there are 100
pairs (F1-R1, F1-R2, …, F1-R10; F2-R1, F2-R2,…, F2-R10; …;
F10-R1, F10-R2,…., F10-R10) of PCR reactions (Figure 2B). It is
expected that only one or two pairs of PCR reactions will produce
specific PCR products spanning the deletion boundary, since the
other primer pairs should be too far from the breakpoint for
efficient amplification. Then aliquots from each reaction can be
mixed to hybridize on a single genomic tiling array. Unlike
traditional array-CGH, it is expected that only spots representing
genomic sequences near the breakpoints will be theoretically lit up,
which was confirmed in the following experiments.
In order to increase the throughput and reduce the cost of
reagents, every forward (F1-10) and reverse (R1-10) primer group
can have multiple primers. Therefore, every PCR group (for
example F1-R1) pair becomes multiplex PCR. Therefore, we
designated this procedure as Primer Approximation Multiplex
PCR (PAMP).
Deletion breakpoint cloning by PAMP and
minigenomic tiling array
We reported previously that the Detroit 562 cell line has an
approximate 20 kb (including INK4A exons 1 and 2) deletion on
chromosome 9p21 [3]. We used this cell line to test our deletion
scanning approach. Four groups (FA,F B,R Y and RZ) of primers
were used for four PAMP reactions (Figure 3A) using genomic
DNA template either from Detroit 562 (CDKN2A deficient) or
Figure 1. The CDKN2A locus. The genomic map covers about 55 kb around CDKN2A according to Ensemble [59]. CDKN2A/B is located at
chromosome 9p21 and their RNA products are encoded by the reverse strand. CDKN2A encodes 2 proteins (p16
INK4A and p14
ARF) that share the same
exons 2 and 3. The first exons of INK4A and ARF are about 20 kb apart. CDKN2B encodes p15
INK4B that is homologous to p16
INK4A. In addition to
transcripts, the map also shows repetitive sequences (Repeat) and available BAC clone (Human tilepath clones), RP11-149I2.
doi:10.1371/journal.pone.0000380.g001
Figure 2. Primer Approximation Multiplex PCR (PAMP). The efficiency
of PCR amplification is inversely related to the distance of upstream and
downstream primers. In this example, primers to amplify genomic
sequences around the locus of interest (LOI) are divided into 20 groups:
10 each for forward (F1–F10) and reverse (R1-R10) groups (A). While all
of the possible forward and reverse primer pairs are too far to each
other for PCR amplification in wild type genome, certain pair of primers
is brought closer (‘‘approximated’’) due to deletion (F3 and R3) in
mutated genome. Multiplex PCR reactions are set and represented as
a matrix to include one forward and one reverse primer group. The
expected PCR results are shown as gray scale shadows in the matrix (B).
This example shows that only group pairs close to breakpoint give PCR
products (F3-R3, F3-R4, F4-R3).
doi:10.1371/journal.pone.0000380.g002
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reaction products were pooled and labeled for hybridization on an
INK4A minigenomic tiling array that covers about 25 kb, including
all of the exons of INK4A. As predicted in Figure 2, only spots with
probes close to the breakpoints hybridized to the amplicons when
Detroit 562 genomic DNA was used as a template (Figure 3B).
Almost no signal was detected when HEK293 genomic DNA was
used as a template. The control HEK293 sample had a signifi-
cantly higher signal on Cot-1 DNA spots despite its general
absolute signal intensity is low.
In addition, four separate arrays were used to hybridize the
individual PAMP products described above. A simple plot of signal
intensity ratio of mutant/WT PCR products on the tiling array
revealed the genomic location of the breakpoint (Figure 4). This
analysis shows a very straightforward readout—the location of the
deletion is bordered by two peaks. Only FB-RY (array 27) and all
products pooling (array 29) produce the same result as shown in
Figure 3. In contrast, the other three pairs yielded only faint
background signals on the arrays. This result indicates that PAMP
product pooling with a single array analysis gives the same break-
point information as four individual arrays. The data support the
original experimental predictions, and suggest that the procedure
should be generally applicable for deletion and translocation
scanning.
In order to pinpoint more precisely the area of deletion, nested
PCR with pairs of specific primers was designed according to the
earlier PAMP results. The PCR product was labeled for array
hybridization, yielding a result very similar to that shown in
Figure 4 and is shown in Figure 5A. Furthermore, the single major
product of the PCR reactions was resolved by agarose gel electro-
phoresis, excised, extracted and sequenced (Figure 5B). The break-
point cloned is in agreement with two other reports (Figure 5B)
[37,38].
To mimic the heterogeneous population of cancer and host cells
typically found in solid tumors, various amounts of genomic DNA
derived from Detroit 562 (mutant) and HEK293 (wild type) were
mixed for PAMP and array hybridization. In order to test the
sensitivity of our approach, we performed a titration experiment.
The total genomic DNA for each assay was kept constant (100 ng).
This is equivalent to about 28,000 copies of haploid genome
(based on the estimate of 2.8610
5 molecules/mg of haploid
genome). The CDKN2A deleted cell line Detroit 562 was serially
diluted with CDKN2A wild type HEK293 as shown in the Table 1.
The assay was able to detect approximately 1 breakpoint sequence
in the presence of an approximately 2000 fold excess of wild-type
genome with sensitivity of 5–16 such molecules (Table 1). Thus,
the PAMP approach provides a method for detecting genomic
DNA deletions in the presence of more than 99.9% wild type
DNA.
Figure 3. Breakpoint identification by PAMP with an INK4A
minigenomic tiling array. (A) Five groups of primers (FA,F B,R x,R Y
and RZ, the small arrows and arrow heads) near the potential
breakpoints were generated for PAMP based on our previous mapping
[3]. The mapped CDKN2A breakpoints of the Detroit 562 cell line
(Figure 5) are indicated for clarification. The ‘‘E1’’, ‘‘E2’’ and ‘‘E3’’
designations (blue fonts) are the relative positions of INK4A exons. The
first exon of ARF is further to the right of this diagram and is not
covered by this array. The tiling probes for the array are indicated with
two alternating colors (short black and orange lines) for ease of
identification. (B) The first row of the INK4A minigenomic array was
spotted with the tiling probes shown in panel A. Cot-1 DNA (repetitive
sequence of genomic DNA) spots are indicated on this array. The rest of
the spots are herring sperm DNA. Both Cot-1 and herring sperm DNA
are used as nonspecific controls. This array was hybridized with labeled
samples derived from two cell lines. The same sets of primers (FA,F B,R Y
and RZ) were used for PAMP reactions on Detroit 562 (mutant) and
HEK293 (wild type) genomic DNA to map the potential CDKN2A
breakpoints. The amplicons were labeled with different dyes, yielding
a green signal (Cy-3) for the mutant sample and a red signal (Cy-5) for
the wild type sample, to be simultaneously hybridized on the array
(two-color array). The two green spots on the first row revealed the
breakpoint location as been discussed in Figure 2.
doi:10.1371/journal.pone.0000380.g003
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Figure 4. Pooling of individual PAMP reactions for single array hybridization. Four groups (FA,F B,R Y and RZ) of primers were used for four PAMP
reactions each by pairing all of the possible forward and reverse primer groups using Detroit 562 (mutant) and HEK293 (control) as templates. The
procedure has been briefly described in Figure 3. The products were labeled and used for array hybridization: FA-RY for array 25; FA-RZ for array 26; FB-
RY for array 27 and FA-RZ for array 28. Aliquots of the individual PAMP samples were also pooled together and labeled for array hybridization (array 29,
its array image is shown in Figure 3B). The results are presented with ratio signal intensity (Y-axis) of samples from Detroit 562 (mutant) and HEK293
(control) against the probe location (X-axis). The breakpoints can be identified through this plot by finding the two peaks that are analogous to the
bright green spots in Figure 3B.
doi:10.1371/journal.pone.0000380.g004
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another cell line. Because our array only covers 25 kb of the
genome, we scanned our previous mapping information on 100
cell lines to find one that might have breakpoints within this region
[3,33]. The Hs578T breast cancer cell line has a deletion in
p16
INK4A exons 1-3. With primers within and telomeric (FA and
RX groups, Table 2) to the genomic fragment, we performed
PAMP and array hybridization, and identified a single spot on the
array (shown as a single peak in Figure 6A). The sequence of this
probe is located from 69971 to 71219 in the RP11-149I2 BAC
sequence (GenBank accession AL449423). Therefore, the centro-
meric end of the breakpoint should be located near this region.
Uniplex PCR with primers from the two groups for PAMP was
performed for sequencing. A PCR product about 2 kb was
generated with a pair of primers and was subjected to direct
sequencing (Figure 6B). The centromeric end of the breakpoint
identified by PAMP is consistent with a previous report [37]. The
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Figure 5. Breakpoint mapping of Detroit 562 cell line. To map the exact breakpoint, a nested set of PCR primers were designed for uniplex PCR
based on the previous PAMP results (Figures 3 and 4). The PCR products were used for labeling and hybridized on the array and also for agarose gel
electrophoresis. The array data is shown as the same plot in Figure 4. A single major band on the agarose gel was excised and purified for sequencing
(B). The breakpoint is indicated (from #21975226 to #21960809 according to NCBI human genome sequence build 36).
doi:10.1371/journal.pone.0000380.g005
Table 1. The sensitivity of PAMP assay
......................................................................
Complexity Detroit
562: Total
Absolute genome copy
number of Detroit 562 Array Result
1:1 28000 P
1:10 2800 P
1:50 560 P
1:100 280 P
1:200 140 P
1:600 47 P
1:1800 16 P
1:5400 5 N
0:1 0 N
Total input of genomic DNA is 100 ng for each reaction.
P: positive. N: Negative
doi:10.1371/journal.pone.0000380.t001
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Table 2. Primers for PAMP
......................................................................
Primer Sequence Location
FA1 TTTCTGCTATTTCCTGAAC 55654–55672
FA2 CAGTATGCGTGTGCTCAG 56279–56296
FA3 AAATAGAGGTGCAGTGCTC 57913–57931
FA4 GGGAAGGCATATATCTACG 58800–58818
FB1 ATTAATTGTGCTTGAAGAGG 60231–60250
FB2 AGGCCTTGAACTAGCAGAG 61358–61376
FB3 CCAGGTTTATGATTTGAGAG 63412–63431
RX1 GAAATGTGTTCCCTCCCTC 68061–68043
RX2 GGATAATGGACTTCAATTTC 68846–68827
RX3 CCATCCTCTCTACTCATAAG 70476–70457
RX4 TCATTAGAAAGGCCATGGAC 71219–71200
RX5 TAAATTAAAGGGATGCATGG 72297–72278
RY1 TAATTATTGCTTTGTGTGGG 74054–74035
RY2 ATGATTAAGGATATGGTTGG 74555–74536
RY3 GTATTCAGACTCCTGGTATG 76585–76566
RZ1 TTATGATCCAGACCAGGCTC 78114–78095
RZ2 TTATCTTTGAATTGAGGTCC 78543–78524
RZ3 GGGTGGTTGAAGAAATTCTC 79277–79258
The location of the primers is numbered according to the nucleotide sequence
of BAC clone RP11-149I2 (GenBank accession: AL449423)
doi:10.1371/journal.pone.0000380.t002
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PLoS ONE | www.plosone.org 4 April 2007 | Issue 4 | e380telomeric end of the breakpoint was inferred from the primers
used for PAMP and also confirmed by direct sequencing, although
there was no genomic probe near the breakpoint that was included
on the array.
DISCUSSION
We have developed a general strategy that can be applied for
pinpointing the genomic breakpoints in unpurified primary
cancers. The amplification and tiling protocol described here
allows for simple and precise CDKN2A breakpoint cloning, using
contaminated DNA as a template. In contrast to the current
available techniques for deletion mapping (including Southern
blotting, fluorescent in situ hybridization, real time PCR, and array
CGH) that rely on the absence of a detectable wild type signal,
PAMP directly measures the deleted DNA. Therefore, this
approach is much less vulnerable to problems associated with
normal cell contamination. The experimental procedure is robust
enough to detect deletions in the presence of at least 99.9% wild
type sequence contamination, which could not be achieved by
other procedures [3,5,26,27,28,33,35,39].
Primer approximation PCR screening has been a useful tool for
isolating deletion mutants in C. elegans [36]. The method relies on
identifying a single band that is the product of a successful PCR
reaction when a pair of specific primers is brought together by
deletion, on an agarose gel. The procedure can only identify
deletions that happen in a very small genomic fragment (3 kb) in
a relatively low throughput fashion. It also suffers from relatively
high false positive rate because the identity of the bands on the
agarose gel is difficult to know. However, by applying multiplex
PCR together with a genomic tiling array, one can simultaneously
screen a wider range of genomic regions [40]. In addition,
preferential amplification of the sequences near the breakpoints
generates a relatively straightforward readout on the tiling array.
The signal to noise ratio on the hybridized spots is obvious com-
pared to the readout from array CGH (see Figure 4). The junction
can be readily identified as long as one end of the nearby genomic
location of the breakpoints is covered by the tiling array, as shown
in the case of Hs578T breast cancer cell (Figure 6). Since high-
density genomic tiling arrays are commercially available, this
approach can be easily adopted. In addition, high-throughput
genome sequencing technology may also pinpoint the exact
breakpoint sequence after PAMP, bypassing the need for array
hybridization [41,42,43].
We used multiplex PCR to reduce the workload and cost for
PAMP. We were able to multiplex 28 primers easily in a single
PCR reaction. Theoretically, one can cover over 90% of the
0.5 Mb of genomic fragment around CDKN2A locus with a total of
500 primers in one single PCR reaction through computational
simulation, which will be described elsewhere (manuscript sub-
mitted). A recent paper reported a successful multiplex PCR with
more than 1000 primer pairs through the aid of computational
design [44]. The PAMP approach targets deletion sizes between
10 kb and 1 Mb. The smaller or larger deletions can be detected
by resequencing and FISH respectively.
Like other PCR technologies, PAMP can be easily adopted to
a robotic system for clinical and research purposes. One example
of a potential clinical application is to use the unique breakpoint
sequence as a personalized cancer-specific biomarker for disease
monitoring after treatment, when the precise breakpoint has been
mapped. For example, unlike many current tumor markers, such
as CA19-9, CA125 and PSA, which are not truly cancer-specific,
the CDKN2A breakpoints are specific and unique for each cancer
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Figure 6. Breakpoint mapping of Hs578T cell line. Two groups of primers: FA (FA1-FA4) and RX (RX1-RX5) were used for PAMP based on our previous
mapping. The product was labeled for array hybridization (A). Only single peak is evident from the plot. It indicates the location of the other
breakpoint is not covered by this minigenomic array. Two primers (RX3 and RX4) located near the genomic location of the probe (human chromosome
9, 21969229 to 21970477, NCBI build 36) that was hybridized and two primers (FA1 and FA2) located outside the array coverage were chosen for
uniplex PCR. The FA2-RX3 pair is expected to have the shortest distance when a deletion occurs. A band of about 2 kb on agarose gel was excised
from the gel, purified and sequenced (B). The breakpoint and location is indicated (from #21955827 to #21968338 according to NCBI human
genome sequence build 36).
doi:10.1371/journal.pone.0000380.g006
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PCR, can be designed to monitor the status of cancer progression
in the blood or other body fluids. The assay should be very specific
because amplification is expected to occur only from deletion-
containing DNA due to very long distance between the primers in
the wild type genome (see Figure 2). This is analogous to the
detection of a foreign virus sequence, which has been applied as
a useful biomarker for Epstein-Barr virus associated nasopharyn-
geal carcinoma [45,46].
Our approach can also ease traditional labor-intensive experi-
ments that aim to understand how genomic breakpoints are
generated during cancer development, particularly in primary
tumors. Although illegitimate V(D)J recombination may be
responsible for creating CDKN2A deletions in acute lymphoblastic
leukemia, more breakpoint sequence data will be needed for other
types of cancers to delineate the molecular mechanisms
[37,38,47,48]. Furthermore, the technique described in this paper
can be used not only for deletion mapping, but it can also be
applied to map other types of genomic rearrangement, such as
translocations and inversions. Similar to the case of genomic
deletion (see Figure 2), only ‘‘approximated’’ primers can generate
amplicons when those primers are near the genomic fragments
that are repositioned in translocations and inversions.
Using breakpoint sequences as cancer-specific biomarkers to
monitor minimal residual diseases has been explored [49,50,51,
52,53]. Disease monitoring based on personalized genomic DNA
breakpoint is considered to be highly attractive approach for
several reasons[49]. First, many genomic DNA rearrangements
are directly related to oncogenic process, therefore, are truly
cancer-specific and stable over time. This is in contrast to more
convenient Ig/TCR rearrangement based assay. Indeed, we found
exactly the same CDKN2A breakpoints of the two cell lines used in
this study as reported by others. Second, the DNA is more stable
than RNA although it is easier to map fusion transcript if it exists,
such as BCR-ABL. Third, the genomic breakpoints are very likely
to be different from each patient and become personalized
biomarkers, thereby, reducing the risk of false positive results due
to cross contamination. However, this is also the biggest hurdle to
overcome. For example, many efforts to improve the PCR
amplification range for detecting C-MYC/immunoglobulin trans-
locations have had limited success because the breakpoints are
scattered across a more than 300 kb region [54,55,56]. Our
strategy may be useful for such application.
Our approach aims to identify breakpoints within a 1 Mb
genomic fragment as FISH or other cytogenetic techniques are
available for larger genomic rearrangements and the cost and labor
significantly increase when the target region expands. We are able to
inexpensively produce a tiling array covering a genomic fragment of
0.5 Mb around the CDKN2A with 1 kb resolution. We are currently
working on methods to increase multiplexing and reduce the volume
of each PAMP reaction for broader applications.
MATERIALS AND METHODS
Cell culture and sample preparation
The cell lines described in the paper were obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and
cultured as recommended. The genomic DNA was extracted with
DNAzol (Molecular Research Center, Inc., Cincinnati, OH)
following the instructions from the manufacturer.
Minigenomic tiling array
We created an INK4A minigenomic tiling array covering a 25 kb
fragment in the CDKN2A locus for proving the concept of our
approach. DNA probes were generated by PCR with BAC clone
RP11-149I2 (obtained from BACPAC Resources Center at
Children’s Hospital Oakland Research Institute, Oakland, CA)
as template and avoiding the repetitive genomic sequences that
were predicted by RepeatMasker. The PCR products were
purified with DNA Clean-up and Concentrator-5 (Zymo Research,
Orange, CA), resuspended in 36SSC and printed on poly-L-lysine
slides at 0.1 mg/ml along with Human Cot-1 DNA (Invitrogen,
Carlsbad, CA), which is enriched for repetitive sequences, and
herring sperm DNA (Promega, Madison, WI), which was used as
nonspecific control. The printing procedure has been described and
essentially followed the manual of the DeRisi arrayer with silicon
microcontact printing pins (Parallel Synthesis Technologies, Inc.
Santa Clara, CA) [57,58]. Arrays were post-processed with succinic
anhydride-based method for blocking before hybridization as
previously described [57]. The protocols related to array printing
and hybridization in this paper generally can be found in micro-
arrays.org (http://derisilab.ucsf.edu/microarray/protocols.html).
Primer-Approximation Multiplex PCR (PAMP) and
array hybridization
A simplified PAMP scheme is shown in Figure 2. A series of
primers (Table 2) toward INK4A exons 1-2 along the CDKN2A
locus were synthesized by Integrated DNA Technologies (Coral-
ville, IA). Groups of forward and reverse primers (250 nM each in
the final reaction) were used to generate amplicons from 0.1 mgo f
genomic DNA templates in a total of 10 ml of solution mixing with
10 ml of Taq 26Master Mix (New England Biolabs, Ipswich, MA).
The reaction was assembled at 4uC in a PCR workstation and
transferred to a thermocycler with the block preheated to 94uC.
The cycling conditions were a 3-minute denaturation step at 94uC
followed by 35 cycles at 92uC for 30 sec, 55uC for 30 sec and 68uC
for 2.5 minutes with a final extension step at 68uC for 5 minutes.
One ml of unpurified product was subsequently used as templates
for another round of amplification to label the amplicons with the
samePCR protocol except that dTTP was replaced bya 4:1 mixture
of aminoallyl dUTP (Ambion, Austin, TX) and dTTP for probe
labeling. The labeled amplicons were purified with DNA Clean-up
and Concentrator-5 columns, eluted in 9 ml of sodium bicarbonate
(pH 9.0) and coupled with 1 ml of DMSO dissolved Cy3 or Cy5
NHS esters (GE Healthcare, Piscataway, NJ) for 30 to 60 minutes.
TheCy3andCy5labeledampliconswerepurifiedwithDNAClean-
up and Concentrator-5 columns and eluted with 10 mlo f1 0m M
Tris-HCl (pH 8.0). Paired Cy3 and Cy5 labeled amplicons were
combined with 3.6 mlo f2 0 6SSC, 0.5 ml of Hepes (pH 7.0) and
finally 0.5 ml of 10% SDS. The mixed solution was heated for
2 minutes at 95uC, cooled to room temperature and hybridized to
the minigenomic tiling arrays at 63uC overnight essentially as
previously described [57,58]. The hybridized arrays were washed
and scanned with GenePix 4000B scanner (Molecular Device,
Sunnyvale, CA) and analyzed by GenePix Pro 6.0 software.
Tiling array data analysis
The human Cot-1 DNA and herring sperm DNA were designed
to be positive and negative controls respectively and spotted
multiple times on the array (see Figure 3). To normalize for day-to-
day and sample-to-sample variation, the median intensity of all
features representing herring sperm DNA (I50%-HS) were used to
divide the intensity (IG) of each feature representing genomic
probes. Each (IG):(I50%-HS) ratio, the normalized genomic probe
signal, was plotted at the Y-axis against the corresponding probe’s
genomic location at the X-axis to ease data interpretation (see
Figure 4).
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To confirm CDKN2A breakpoint mapping by PAMP approach,
the genomic fragments flanking the breakpoints were cloned by
traditional PCR approaches guided by the results from PAMP.
Two examples are given in this paper.
Detroit 562 cell line: The nested approach was used to clone the
CDKN2A breakpoint in Detroit 562 human epithelial carcinoma
cells. The primers were designed with clues from the PAMP
experiment (see Figures 3 and 4). External primers (AGGTTTG-
GTTAAGAGTCGTTC and AAGATCTATATGGTGGCCTT-
TAG) were used for 35 cycles of PCR (92uC, 30 seconds; 55uC,
30 seconds; 68uC, 2 minutes). The two sets of internal primers
(ATGCTAGCTGTAACTGGAGC and CTTAAGGCTAAAT-
TGACTTG; GGCTTAGAGCTAACTCTTCACCC and TAT-
GTGTGTGTGTGTCTGTGTGATG) were used for the second
PCR reaction under the same conditions. A single band about
1 kb in size was excised and extracted with Qiaquick gel extraction
kit (Qiagen, Valencia, CA). The purified product was directly
sequenced with internal primers.
Hs578T cell line: Four sets of uniplex PCR reactions were
performed by pairing 2 single forward (FA1 and FA2) and 2 single
reverse (RX3 and RX4) primers. The PCR program was the same
as that for PAMP. The products were analyzed by agarose gel
electrophoresis. A single band from the shortest distance pair (FA2-
RX3) was excised and sequenced with an internal primer.
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